Praneet C. Kaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Praneet C. Kaki has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
Maurits Boon
Department of Otolaryngology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
10 shared publications- Colin Huntley
Thomas Jefferson University Sidney Kimmel Medical College Philadelphia Pennsylvania USA
9 shared publications - Aman M. Patel
Rutgers New Jersey Medical School Newark New Jersey USA
7 shared publications Ryan M. Carey
Department of Otorhinolaryngology–Head and Neck Surgery University of Pennsylvania Philadelphia Pennsylvania USA
7 shared publications- Robert M. Brody
Department of Otorhinolaryngology—Head and Neck Surgery University of Pennsylvania Philadelphia Pennsylvania USA
6 shared publications Erin Creighton
Department of Otolaryngology & Sleep Medicine Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
5 shared publications
Latest Publications
- 16 November 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Evaluating the Geriatric Nutritional Risk Index for Predicting Outcomes Following Head and Neck Free‐Flap Reconstruction
Objective: Malnutrition has been associated with adverse outcomes among head and neck cancer (HNC) patients. Despite this, there is no universally accepted standard for screening of nutrition‐related risk. This study aimed to determine if nutrition‐related risk, as defined by the Geriatric Nutritional Risk Index (GNRI), is associated with adverse postoperative outcomes following microvascular free tissue transfer (MFTT) for HNC. Study Design: Retrospective cohort study. Setting: Population‐based study using the 2010 to 2022 American College of Surgeons National Surgical Quality Improvement Program (ACS‐NSQIP). Methods: Patients aged >65 years who underwent MFTT for HNC were stratified into 3 cohorts based on preoperative GNRI: no nutrition‐related risk (GNRI > 98), moderate nutrition‐related risk (GNRI 92‐98), and major nutrition‐related risk (GNRI < 92). After adjusting for potential confounders, multivariable logistic regression models were performed to assess the association between GNRI and postoperative outcomes. Results: Of 1586 patients, 945 (59.6%) patients had a GNRI corresponding with no nutrition‐related risk, 346 (21.8%) had moderate nutrition‐related risk, and 295 (18.6%) had major nutrition‐related risk. On multivariable regression, both moderate and major nutrition‐related risk cohorts were associated with surgical, medical, and Clavien‐Dindo grade IV (CDIV) complications, along with non‐home discharge, respectively ( P < .05). Conclusions: Nutrition‐related risk as defined by the GNRI is associated with surgical, medical, and CDIV complications, and non‐home discharge following MFTT for HNC. Prospective studies are needed to validate the utility of the GNRI as a preoperative risk stratification tool to optimize surgical outcomes following MFTT for HNC. Level of Evidence: 4.
- 16 November 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Evaluating the Geriatric Nutritional Risk Index for Predicting Outcomes Following Head and Neck Free‐Flap Reconstruction
Objective: Malnutrition has been associated with adverse outcomes among head and neck cancer (HNC) patients. Despite this, there is no universally accepted standard for screening of nutrition‐related risk. This study aimed to determine if nutrition‐related risk, as defined by the Geriatric Nutritional Risk Index (GNRI), is associated with adverse postoperative outcomes following microvascular free tissue transfer (MFTT) for HNC. Study Design: Retrospective cohort study. Setting: Population‐based study using the 2010 to 2022 American College of Surgeons National Surgical Quality Improvement Program (ACS‐NSQIP). Methods: Patients aged >65 years who underwent MFTT for HNC were stratified into 3 cohorts based on preoperative GNRI: no nutrition‐related risk (GNRI > 98), moderate nutrition‐related risk (GNRI 92‐98), and major nutrition‐related risk (GNRI < 92). After adjusting for potential confounders, multivariable logistic regression models were performed to assess the association between GNRI and postoperative outcomes. Results: Of 1586 patients, 945 (59.6%) patients had a GNRI corresponding with no nutrition‐related risk, 346 (21.8%) had moderate nutrition‐related risk, and 295 (18.6%) had major nutrition‐related risk. On multivariable regression, both moderate and major nutrition‐related risk cohorts were associated with surgical, medical, and Clavien‐Dindo grade IV (CDIV) complications, along with non‐home discharge, respectively ( P < .05). Conclusions: Nutrition‐related risk as defined by the GNRI is associated with surgical, medical, and CDIV complications, and non‐home discharge following MFTT for HNC. Prospective studies are needed to validate the utility of the GNRI as a preoperative risk stratification tool to optimize surgical outcomes following MFTT for HNC. Level of Evidence: 4.
- 27 April 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (9) , 714-719
Medicare Reimbursement Trends in Sleep Surgery: A 2 Decade Analysis of the Most Billed Codes
Objectives: The prevalence of sleep-disordered breathing, including obstructive sleep apnea, has driven the rapid growth of sleep surgery as a subspecialty. Medicare reimbursement plays a pivotal role in the economic viability of sleep surgery, but trends remain understudied. This study analyzes reimbursement trends for commonly performed sleep surgery procedures from 2000 to 2024, assessing inflation-adjusted changes in facility-based professional reimbursement. Methods: The 11 most frequently billed sleep surgery procedures at a single institution in 2024 were identified. Medicare data on facility-based professional reimbursement were extracted from 2000 to 2024 using the CMS Physician Fee Schedule. Inflation adjustments were applied using the CPI Inflation Calculator. Year-to-year percentage changes and linear regression analyses were performed. Results: Among the analyzed CPT codes, a consistent decline in inflation-adjusted facility prices was observed, with an average aggregate decrease of 39.8%. The most pronounced decline was in CPT 42975 (Drug-Induced Sleep Endoscopy), which decreased by 72.1% ( R 2 = .88). Other procedures, such as CPT 30140 (Submucous Resection of Inferior Turbinate) and CPT 31231 (Diagnostic Nasal Endoscopy), experienced aggregate declines exceeding 58%. Procedures like CPT 30130 (Excision of Inferior Turbinate) showed relatively stable pricing with a 2.6% aggregate reduction. Conclusion: The substantial decline in inflation-adjusted facility prices for sleep surgery procedures underscores challenges in sustaining the financial and operational viability of this growing subspecialty. Reduced reimbursement may hinder innovation, training, and resource allocation, with potential downstream impacts on patient access and care. Policymakers should consider these findings to ensure equitable and sustainable support within the healthcare system. Level of evidence: 4.
- 27 April 2026
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (9) , 714-719
Medicare Reimbursement Trends in Sleep Surgery: A 2 Decade Analysis of the Most Billed Codes
Objectives: The prevalence of sleep-disordered breathing, including obstructive sleep apnea, has driven the rapid growth of sleep surgery as a subspecialty. Medicare reimbursement plays a pivotal role in the economic viability of sleep surgery, but trends remain understudied. This study analyzes reimbursement trends for commonly performed sleep surgery procedures from 2000 to 2024, assessing inflation-adjusted changes in facility-based professional reimbursement. Methods: The 11 most frequently billed sleep surgery procedures at a single institution in 2024 were identified. Medicare data on facility-based professional reimbursement were extracted from 2000 to 2024 using the CMS Physician Fee Schedule. Inflation adjustments were applied using the CPI Inflation Calculator. Year-to-year percentage changes and linear regression analyses were performed. Results: Among the analyzed CPT codes, a consistent decline in inflation-adjusted facility prices was observed, with an average aggregate decrease of 39.8%. The most pronounced decline was in CPT 42975 (Drug-Induced Sleep Endoscopy), which decreased by 72.1% ( R 2 = .88). Other procedures, such as CPT 30140 (Submucous Resection of Inferior Turbinate) and CPT 31231 (Diagnostic Nasal Endoscopy), experienced aggregate declines exceeding 58%. Procedures like CPT 30130 (Excision of Inferior Turbinate) showed relatively stable pricing with a 2.6% aggregate reduction. Conclusion: The substantial decline in inflation-adjusted facility prices for sleep surgery procedures underscores challenges in sustaining the financial and operational viability of this growing subspecialty. Reduced reimbursement may hinder innovation, training, and resource allocation, with potential downstream impacts on patient access and care. Policymakers should consider these findings to ensure equitable and sustainable support within the healthcare system. Level of evidence: 4.
- Open Access
- 29 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (9) , 4072-4080
Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery
Objectives: To establish how celecoxib use after tonsillectomy and adenoidectomy (T&A) and modified uvulopalatopharyngoplasty (UPPP) affect pain scores and opioid consumption. Methods: Patients undergoing T&A or UPPP with tonsillectomy (May–October 2024) completed surveys on postoperative days (POD) 0, 1, 5, and 10 to assess pain scores and opioid use. All patients received a multimodal pain regimen, and cohorts were based on the prescription of celecoxib. The noncelecoxib cohort was a historical control group obtained via study data from Butkus et al. (December 2020–January 2023) . Wilcoxon rank‐sum and chi‐squared tests were performed using R Studio. Results: Eighty patients were included (mean 33.0 years [SD = 12]), 66% female; 34% male; 55% Caucasian. The celecoxib cohort ( N = 38) consumed an average of 66.2 mL (SD = 62.1) of opioids, and the non‐celecoxib cohort ( N = 42) received an average of 118.4 mL (SD = 91.6) ( p = 0.021). There were no significant differences in pain scores reported on POD 1, 5, or 10 ( p = 0.5, p = 0.2, p = 0.6, respectively). Conclusion: The addition of postoperative celecoxib resulted in a significant decrease in mean opioid consumption. Our data also demonstrate that postoperative pain was controlled similarly based on patient reported pain scores, regardless of celecoxib consumption. Further investigation is warranted with larger sample sizes to determine the efficacy of postoperative celecoxib use. Level of Evidence: 3.
- 29 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (9) , 4072-4080
Open AccessPostoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery
Objectives: To establish how celecoxib use after tonsillectomy and adenoidectomy (T&A) and modified uvulopalatopharyngoplasty (UPPP) affect pain scores and opioid consumption. Methods: Patients undergoing T&A or UPPP with tonsillectomy (May–October 2024) completed surveys on postoperative days (POD) 0, 1, 5, and 10 to assess pain scores and opioid use. All patients received a multimodal pain regimen, and cohorts were based on the prescription of celecoxib. The noncelecoxib cohort was a historical control group obtained via study data from Butkus et al. (December 2020–January 2023) . Wilcoxon rank‐sum and chi‐squared tests were performed using R Studio. Results: Eighty patients were included (mean 33.0 years [SD = 12]), 66% female; 34% male; 55% Caucasian. The celecoxib cohort ( N = 38) consumed an average of 66.2 mL (SD = 62.1) of opioids, and the non‐celecoxib cohort ( N = 42) received an average of 118.4 mL (SD = 91.6) ( p = 0.021). There were no significant differences in pain scores reported on POD 1, 5, or 10 ( p = 0.5, p = 0.2, p = 0.6, respectively). Conclusion: The addition of postoperative celecoxib resulted in a significant decrease in mean opioid consumption. Our data also demonstrate that postoperative pain was controlled similarly based on patient reported pain scores, regardless of celecoxib consumption. Further investigation is warranted with larger sample sizes to determine the efficacy of postoperative celecoxib use. Level of Evidence: 3.
- Open Access
- 23 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (7) , 3262-3270
Modified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP ‐Intolerant OSA Patients
Objective: The modified sleep apnea severity index (mSASI) combines patient anatomy, weight, sleep study metrics, and symptoms into a composite OSA index ranging from 1 (least severe) to 3 (most severe). Our study aims to assess the association between the mSASI and cardiovascular (CV) risk factors in patients undergoing sleep surgery. Study Design: Retrospective cohort review. Setting: Single‐institution tertiary care center. Methods: CPAP‐intolerant OSA patients who underwent hypoglossal nerve stimulation, maxillomandibular advancement, or expansion sphincter pharyngoplasty at our institution from 2014 to 2021 were included. Cardiovascular comorbidities and 5‐year Framingham Risk Score (FRS) were assessed at the preoperative visit. Chi‐squared and Wilcoxon rank sum test analyses were performed using R Studio. Results: Of the 209 patients included, 118 had an mSASI = 1, 71 had an mSASI = 2, and 20 had an mSASI = 3. Patients with an mSASI of 2 or 3 were more likely to have HTN (33% vs 51%, p = 0.011). Baseline mSASI ( β = 4.4, 95% CI 0.04–8.7) and age ( β = 1.3, 95% CI 1.0–1.6) were independently associated with increased FRS on multivariable linear regression ( p < 0.05). However, this association did not persist in secondary models excluding constituent components of mSASI and FRS. Conclusions: The mSASI may offer additional benefits in assessing OSA risk severity based on CV risk factors compared to the AHI alone. However, given that this association was not replicated in the secondary analysis, further research is needed to evaluate the utility beyond its individual factors and traditional metrics alone. Level of Evidence: 4.
- 23 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (7) , 3262-3270
Open AccessModified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP ‐Intolerant OSA Patients
Objective: The modified sleep apnea severity index (mSASI) combines patient anatomy, weight, sleep study metrics, and symptoms into a composite OSA index ranging from 1 (least severe) to 3 (most severe). Our study aims to assess the association between the mSASI and cardiovascular (CV) risk factors in patients undergoing sleep surgery. Study Design: Retrospective cohort review. Setting: Single‐institution tertiary care center. Methods: CPAP‐intolerant OSA patients who underwent hypoglossal nerve stimulation, maxillomandibular advancement, or expansion sphincter pharyngoplasty at our institution from 2014 to 2021 were included. Cardiovascular comorbidities and 5‐year Framingham Risk Score (FRS) were assessed at the preoperative visit. Chi‐squared and Wilcoxon rank sum test analyses were performed using R Studio. Results: Of the 209 patients included, 118 had an mSASI = 1, 71 had an mSASI = 2, and 20 had an mSASI = 3. Patients with an mSASI of 2 or 3 were more likely to have HTN (33% vs 51%, p = 0.011). Baseline mSASI ( β = 4.4, 95% CI 0.04–8.7) and age ( β = 1.3, 95% CI 1.0–1.6) were independently associated with increased FRS on multivariable linear regression ( p < 0.05). However, this association did not persist in secondary models excluding constituent components of mSASI and FRS. Conclusions: The mSASI may offer additional benefits in assessing OSA risk severity based on CV risk factors compared to the AHI alone. However, given that this association was not replicated in the secondary analysis, further research is needed to evaluate the utility beyond its individual factors and traditional metrics alone. Level of Evidence: 4.
- Open Access
- 22 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71693
Neutrophil‐to‐Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy
Purpose: The neutrophil‐to‐lymphocyte ratio (NLR) is a prognostic marker in cancers treated with immune checkpoint inhibitors (ICI), reflecting the link between inflammation and cancer immune response. This study examines NLR's prognostic value in head and neck squamous cell carcinoma (HNSCC) patients receiving neoadjuvant ICI therapy, focusing on its potential as an independent predictor of overall survival (OS) and disease‐free survival (DFS). Methods: We conducted a retrospective cohort study including three neoadjuvant trials: durvalumab ± metformin, nivolumab ± tadalafil, or nivolumab ± BMS‐986205 from 2017 to 2022. Pre‐treatment NLR was calculated using absolute neutrophil and absolute lymphocyte counts obtained before neoadjuvant ICI initiation. The optimal pre‐treatment NLR cut‐off was identified using receiver operating characteristic (ROC) curve analysis. OS and DFS were assessed using Kaplan–Meier and multivariable Cox proportional hazards regression models. Results: A total of 97 patients met inclusion criteria. NLR < 4.14 was associated with improved overall survival (HR 0.07, 95% CI 0.01–0.30, p < 0.001) and DFS (HR 0.21, 95% CI 0.08–0.54, p = 0.001) compared to NLR ≥ 4.14. NLR < 4.14 remained independently associated with improved OS (HR 0.14, 95% CI 0.02–0.78, p = 0.025) and DFS (HR 0.25, 95% CI 0.07–0.87, p = 0.030) on multivariable Cox regression. The survival benefit of NLR < 4.14 persisted after sub‐stratification for p16 status, ICI pathologic response status, and ICI trial. Conclusion: Low NLR was independently associated with improved OS and DFS among patients with HNSCC who received neoadjuvant ICI. These findings suggest the potential utility of the NLR in improving patient selection.
- 22 March 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (3) , e71693
Open AccessNeutrophil‐to‐Lymphocyte Ratio as a Prognostic Factor of Survival Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy
Purpose: The neutrophil‐to‐lymphocyte ratio (NLR) is a prognostic marker in cancers treated with immune checkpoint inhibitors (ICI), reflecting the link between inflammation and cancer immune response. This study examines NLR's prognostic value in head and neck squamous cell carcinoma (HNSCC) patients receiving neoadjuvant ICI therapy, focusing on its potential as an independent predictor of overall survival (OS) and disease‐free survival (DFS). Methods: We conducted a retrospective cohort study including three neoadjuvant trials: durvalumab ± metformin, nivolumab ± tadalafil, or nivolumab ± BMS‐986205 from 2017 to 2022. Pre‐treatment NLR was calculated using absolute neutrophil and absolute lymphocyte counts obtained before neoadjuvant ICI initiation. The optimal pre‐treatment NLR cut‐off was identified using receiver operating characteristic (ROC) curve analysis. OS and DFS were assessed using Kaplan–Meier and multivariable Cox proportional hazards regression models. Results: A total of 97 patients met inclusion criteria. NLR < 4.14 was associated with improved overall survival (HR 0.07, 95% CI 0.01–0.30, p < 0.001) and DFS (HR 0.21, 95% CI 0.08–0.54, p = 0.001) compared to NLR ≥ 4.14. NLR < 4.14 remained independently associated with improved OS (HR 0.14, 95% CI 0.02–0.78, p = 0.025) and DFS (HR 0.25, 95% CI 0.07–0.87, p = 0.030) on multivariable Cox regression. The survival benefit of NLR < 4.14 persisted after sub‐stratification for p16 status, ICI pathologic response status, and ICI trial. Conclusion: Low NLR was independently associated with improved OS and DFS among patients with HNSCC who received neoadjuvant ICI. These findings suggest the potential utility of the NLR in improving patient selection.
- 30 December 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (6) , 2805-2813
Continuous Sleep Monitoring Using the Withings Sleep Mat to Assess Mean Disease Alleviation in OSA
Objective: This pilot study aims to demonstrate the feasibility of continuous sleep monitoring using the Withings Sleep Mat (WSM) and to illustrate Mean Disease Alleviation (MDA) as a potential metric for assessing real‐world treatment effectiveness among patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) or continuous positive airway pressure (CPAP). Methods: Patients treated with CPAP or HGNS therapy were prospectively recruited. The WSM provided nightly estimations of sleep metrics including AHI, total sleep time, and other non‐apneic metrics over 30‐ and 90‐day periods. MDA integrating treatment efficacy and adjusted compliance was calculated as a composite measure of real‐world treatment effectiveness. Results: A total of 29 patients (mean age 59.8 years; 66% male; 93% White) were included, with 15 treated with CPAP and 14 with HGNS. The 90‐day MDA, calculated using continuous AHI monitoring, was 36.05% for CPAP and 24.06% for HGNS ( p = 0.20). Mean MDA using single‐night sleep study (HGNS) or CPAP download (CPAP) was 81.72% (14.81) among CPAP patients and 51.18% (26.69) among HGNS patients ( p = 0.002). HGNS patients experienced more awakenings (3.23 vs. 2.56, p = 0.031) and snoring episodes (2.86 vs. 1.79, p = 0.029) per night during the 30‐day interval. Conclusion: This study demonstrates the feasibility of calculating MDA through continuous, non‐invasive home monitoring using the WSA, offering a more comprehensive assessment of OSA treatment effectiveness than single‐night studies alone. These findings support further evaluation of continuous home‐based monitoring and integrated metrics like MDA to inform personalized therapy selection and long‐term management. Level of Evidence: 4.
- 30 December 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (6) , 2805-2813
Continuous Sleep Monitoring Using the Withings Sleep Mat to Assess Mean Disease Alleviation in OSA
Objective: This pilot study aims to demonstrate the feasibility of continuous sleep monitoring using the Withings Sleep Mat (WSM) and to illustrate Mean Disease Alleviation (MDA) as a potential metric for assessing real‐world treatment effectiveness among patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) or continuous positive airway pressure (CPAP). Methods: Patients treated with CPAP or HGNS therapy were prospectively recruited. The WSM provided nightly estimations of sleep metrics including AHI, total sleep time, and other non‐apneic metrics over 30‐ and 90‐day periods. MDA integrating treatment efficacy and adjusted compliance was calculated as a composite measure of real‐world treatment effectiveness. Results: A total of 29 patients (mean age 59.8 years; 66% male; 93% White) were included, with 15 treated with CPAP and 14 with HGNS. The 90‐day MDA, calculated using continuous AHI monitoring, was 36.05% for CPAP and 24.06% for HGNS ( p = 0.20). Mean MDA using single‐night sleep study (HGNS) or CPAP download (CPAP) was 81.72% (14.81) among CPAP patients and 51.18% (26.69) among HGNS patients ( p = 0.002). HGNS patients experienced more awakenings (3.23 vs. 2.56, p = 0.031) and snoring episodes (2.86 vs. 1.79, p = 0.029) per night during the 30‐day interval. Conclusion: This study demonstrates the feasibility of calculating MDA through continuous, non‐invasive home monitoring using the WSA, offering a more comprehensive assessment of OSA treatment effectiveness than single‐night studies alone. These findings support further evaluation of continuous home‐based monitoring and integrated metrics like MDA to inform personalized therapy selection and long‐term management. Level of Evidence: 4.
- Open Access
- 14 October 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (3) , 1536-1543
Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes
Objective: The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population. Methods: We conducted a multi‐institutional retrospective review between 2014 and 2023. Patients with prior BS were compared to those without (nBS). A 1:2 propensity score matching (PSM) was performed using age, gender, race, and baseline BMI. Data collected included demographics, pre/post‐operative apnea‐hypopnea index (AHI), body mass index (BMI), and Epworth Sleepiness Score (ESS). Treatment success was defined using Sher15 criteria. Analyses were conducted in R‐Studio. Results: After PSM, 72 patients met inclusion (mean age 61.3 years, 62% male, 83% White), including 24 (33%) with BS. Sher15 response rates were 71% in BS vs. 56% in nBS ( p = 0.2). BS patients had significantly greater mean AHI reductions than NBS (−28.44 ± 16.39 vs. −17.68 ± 21.23; p = 0.009). Both groups had comparable reductions in ESS (−4.67 vs. −3.44; p = 0.2), with a mean postoperative ESS of 6.78 in BS and 6.17 in NBS ( p = 0.5). On multivariable linear regression adjusting for demographics, baseline AHI, and BMI, prior BS was independently associated with greater AHI reduction (β = −8.6; 95% CI −16, −1.1; p = 0.026). Conclusion: Patients with prior BS achieve comparable or superior outcomes following HGNS. Prior weight loss may enhance HGNS effectiveness and merits further study. Level of Evidence: 3.
- 14 October 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (3) , 1536-1543
Open AccessImpact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes
Objective: The effectiveness of hypoglossal nerve stimulation (HGNS) for residual obstructive sleep apnea (OSA) in patients with prior bariatric surgery (BS) has not been previously reported. We evaluate and compare HGNS outcomes in this unique population. Methods: We conducted a multi‐institutional retrospective review between 2014 and 2023. Patients with prior BS were compared to those without (nBS). A 1:2 propensity score matching (PSM) was performed using age, gender, race, and baseline BMI. Data collected included demographics, pre/post‐operative apnea‐hypopnea index (AHI), body mass index (BMI), and Epworth Sleepiness Score (ESS). Treatment success was defined using Sher15 criteria. Analyses were conducted in R‐Studio. Results: After PSM, 72 patients met inclusion (mean age 61.3 years, 62% male, 83% White), including 24 (33%) with BS. Sher15 response rates were 71% in BS vs. 56% in nBS ( p = 0.2). BS patients had significantly greater mean AHI reductions than NBS (−28.44 ± 16.39 vs. −17.68 ± 21.23; p = 0.009). Both groups had comparable reductions in ESS (−4.67 vs. −3.44; p = 0.2), with a mean postoperative ESS of 6.78 in BS and 6.17 in NBS ( p = 0.5). On multivariable linear regression adjusting for demographics, baseline AHI, and BMI, prior BS was independently associated with greater AHI reduction (β = −8.6; 95% CI −16, −1.1; p = 0.026). Conclusion: Patients with prior BS achieve comparable or superior outcomes following HGNS. Prior weight loss may enhance HGNS effectiveness and merits further study. Level of Evidence: 3.
- Open Access
- 10 October 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (5)
Missed Adjuvant Therapy Following Upfront Laryngectomy for Laryngeal Squamous Cell Carcinoma
Objective: To investigate adjuvant therapy considerations, utilization, and associated overall survival (OS) following upfront laryngectomy for laryngeal squamous cell carcinoma (LSCC). Methods: The 2010 to 2017 National Cancer Database was retrospectively reviewed for patients undergoing upfront laryngectomy ( N = 3360). Kaplan–Meier, multivariable binary logistic, and Cox proportional hazards regression models were implemented. Results: Among 2997 patients with consideration(s) for adjuvant radiotherapy (aRT) (i.e., pT3‐4, pN2‐3 classification, lymphovascular invasion, pathologic extranodal extension (pENE), and/or positive surgical margins [PSM]), 1176 (39.2%) did not undergo adjuvant therapy and were considered to have missed aRT. Among 992 patients with consideration(s) for adjuvant chemoradiotherapy (aCRT) (i.e., pENE and/or PSM), 169 (17.0%) underwent aRT alone and were considered to have missed aCRT. Older age and increased distance to the reporting facility were associated with higher adjusted odds of both missed aRT ( p < 0.001) and missed aCRT ( p < 0.025). Patients with pENE only ( N = 343, 57.6%) and pENE and PSM ( N = 96, 56.8%) underwent aCRT more frequently than those with PSM only ( N = 97, 42.5%) ( p < 0.001). Missed aRT was associated with worse OS among 2005 patients with consideration(s) for aRT alone (i.e., pT3‐4, pN2‐3 classification, and/or LVI without pENE or PSM) (aHR 1.23, 95% CI 1.05–1.44, p = 0.011) and among 992 patients with consideration(s) for aCRT (aHR 1.85, 95% CI 1.52–2.24, p < 0.001). Conclusion: Missed aRT following upfront laryngectomy for LSCC occurs frequently and portends worse OS. Identifying patients at risk of off‐guideline management may create opportunities for quality improvement in the multidisciplinary care of patients undergoing upfront laryngectomy for LSCC. Level of Evidence: 4.
- 10 October 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (5)
Open AccessMissed Adjuvant Therapy Following Upfront Laryngectomy for Laryngeal Squamous Cell Carcinoma
Objective: To investigate adjuvant therapy considerations, utilization, and associated overall survival (OS) following upfront laryngectomy for laryngeal squamous cell carcinoma (LSCC). Methods: The 2010 to 2017 National Cancer Database was retrospectively reviewed for patients undergoing upfront laryngectomy ( N = 3360). Kaplan–Meier, multivariable binary logistic, and Cox proportional hazards regression models were implemented. Results: Among 2997 patients with consideration(s) for adjuvant radiotherapy (aRT) (i.e., pT3‐4, pN2‐3 classification, lymphovascular invasion, pathologic extranodal extension (pENE), and/or positive surgical margins [PSM]), 1176 (39.2%) did not undergo adjuvant therapy and were considered to have missed aRT. Among 992 patients with consideration(s) for adjuvant chemoradiotherapy (aCRT) (i.e., pENE and/or PSM), 169 (17.0%) underwent aRT alone and were considered to have missed aCRT. Older age and increased distance to the reporting facility were associated with higher adjusted odds of both missed aRT ( p < 0.001) and missed aCRT ( p < 0.025). Patients with pENE only ( N = 343, 57.6%) and pENE and PSM ( N = 96, 56.8%) underwent aCRT more frequently than those with PSM only ( N = 97, 42.5%) ( p < 0.001). Missed aRT was associated with worse OS among 2005 patients with consideration(s) for aRT alone (i.e., pT3‐4, pN2‐3 classification, and/or LVI without pENE or PSM) (aHR 1.23, 95% CI 1.05–1.44, p = 0.011) and among 992 patients with consideration(s) for aCRT (aHR 1.85, 95% CI 1.52–2.24, p < 0.001). Conclusion: Missed aRT following upfront laryngectomy for LSCC occurs frequently and portends worse OS. Identifying patients at risk of off‐guideline management may create opportunities for quality improvement in the multidisciplinary care of patients undergoing upfront laryngectomy for LSCC. Level of Evidence: 4.
- Open Access
- 7 October 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (5)
Treatment of Biopsy‐Proven Laryngeal Squamous Cell Carcinoma In Situ
Objective: To investigate the impact of clinical surveillance, primary radiotherapy, and primary surgery on overall survival (OS) in laryngeal carcinoma in situ (Cis). Methods: The 2006–2020 National Cancer Database was queried for adults with a biopsy‐proven diagnosis of laryngeal Cis. Multivariable binary logistic and Cox proportional hazards regression models were implemented. Results: Of 3567 unique patients satisfying inclusion criteria, 514 (14.4%) underwent clinical surveillance, 1074 (30.1%) underwent primary radiotherapy, and 1979 (55.5%) underwent primary surgery. Receiving treatment at an academic/research facility was associated with higher odds of undergoing primary surgery compared to primary radiotherapy. Among 646 patients undergoing primary surgery with known pT classification and margins, 570 (76.6%) had pTis and NSM and 174 (23.4%) had pT1 and/or PSM. 5‐year OS of clinical surveillance, primary radiotherapy, and primary surgery was 73%, 81%, and 86%, respectively ( p < 0.001). Patients undergoing primary surgery with invasive or residual disease (i.e., pT1 and/or PSM) had similar 5‐year OS as those without (84% vs. 88%, p = 0.057). Compared with primary radiotherapy, clinical surveillance (aHR 1.29, 95% CI 1.06–1.57, p = 0.003) was associated with worse OS, and primary surgery (aHR 0.80, 95% CI 0.69–0.92, p = 0.003) was associated with higher OS. Conclusion: Primary surgery is associated with higher OS than clinical surveillance and primary radiotherapy among patients with laryngeal Cis. Level of Evidence: 4.
- 7 October 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (5)
Open AccessTreatment of Biopsy‐Proven Laryngeal Squamous Cell Carcinoma In Situ
Objective: To investigate the impact of clinical surveillance, primary radiotherapy, and primary surgery on overall survival (OS) in laryngeal carcinoma in situ (Cis). Methods: The 2006–2020 National Cancer Database was queried for adults with a biopsy‐proven diagnosis of laryngeal Cis. Multivariable binary logistic and Cox proportional hazards regression models were implemented. Results: Of 3567 unique patients satisfying inclusion criteria, 514 (14.4%) underwent clinical surveillance, 1074 (30.1%) underwent primary radiotherapy, and 1979 (55.5%) underwent primary surgery. Receiving treatment at an academic/research facility was associated with higher odds of undergoing primary surgery compared to primary radiotherapy. Among 646 patients undergoing primary surgery with known pT classification and margins, 570 (76.6%) had pTis and NSM and 174 (23.4%) had pT1 and/or PSM. 5‐year OS of clinical surveillance, primary radiotherapy, and primary surgery was 73%, 81%, and 86%, respectively ( p < 0.001). Patients undergoing primary surgery with invasive or residual disease (i.e., pT1 and/or PSM) had similar 5‐year OS as those without (84% vs. 88%, p = 0.057). Compared with primary radiotherapy, clinical surveillance (aHR 1.29, 95% CI 1.06–1.57, p = 0.003) was associated with worse OS, and primary surgery (aHR 0.80, 95% CI 0.69–0.92, p = 0.003) was associated with higher OS. Conclusion: Primary surgery is associated with higher OS than clinical surveillance and primary radiotherapy among patients with laryngeal Cis. Level of Evidence: 4.
- Open Access
- 12 September 2025
- Published by Wiley in Head & Neck
- Vol. 48 (2) , 468-477
Comparing Functional Outcomes Following TORS With Free Flap Reconstruction Using a Radial Forearm vs. Anterolateral Thigh Flap
Background: Free flap reconstruction (FFR) following transoral robotic surgery (TORS) is commonly performed using radial forearm free flaps (RFFF). This study compares patterns of functional recovery between RFFFs and anterolateral thigh flaps (ALTFs). Methods: Retrospective cohort study of patients with oropharyngeal cancer who underwent TORS with FFR (2010–2023) at a tertiary care center. A 1:4 ALTF:RFFF propensity score match was performed. Functional Oral Intake Scale (FOIS) assessed outcomes. Results: The 105 patients were included. ALTF patients had lower FOIS at 6 months (3[2.0, 5.0] vs. 5.0[2.0, 6.0], p = 0.045) and 1 year (5.0[2.0, 6.0] vs. 6.0[5.0, 6.8], p = 0.045), with higher PEG tube rates. ALTFs were used for larger defects (62.95 ± 20.25 cm 2 vs. 51.17 ± 15.11 cm 2 , p = 0.014). Donor site morbidity or postoperative complications were similar between cohorts. Conclusions: ALTFs are suitable for larger defects and lead to slower early functional recovery with higher PEG tube rates compared to RFFFs, with no difference in complications.
- 12 September 2025
- Published by Wiley in Head & Neck
- Vol. 48 (2) , 468-477
Open AccessComparing Functional Outcomes Following TORS With Free Flap Reconstruction Using a Radial Forearm vs. Anterolateral Thigh Flap
Background: Free flap reconstruction (FFR) following transoral robotic surgery (TORS) is commonly performed using radial forearm free flaps (RFFF). This study compares patterns of functional recovery between RFFFs and anterolateral thigh flaps (ALTFs). Methods: Retrospective cohort study of patients with oropharyngeal cancer who underwent TORS with FFR (2010–2023) at a tertiary care center. A 1:4 ALTF:RFFF propensity score match was performed. Functional Oral Intake Scale (FOIS) assessed outcomes. Results: The 105 patients were included. ALTF patients had lower FOIS at 6 months (3[2.0, 5.0] vs. 5.0[2.0, 6.0], p = 0.045) and 1 year (5.0[2.0, 6.0] vs. 6.0[5.0, 6.8], p = 0.045), with higher PEG tube rates. ALTFs were used for larger defects (62.95 ± 20.25 cm 2 vs. 51.17 ± 15.11 cm 2 , p = 0.014). Donor site morbidity or postoperative complications were similar between cohorts. Conclusions: ALTFs are suitable for larger defects and lead to slower early functional recovery with higher PEG tube rates compared to RFFFs, with no difference in complications.